Long-Term Azithromycin Maintenance Treatment in Patients with Frequent Exacerbations of Chronic Obstructive Pulmonary Disease

Figures & data

Table 1 Data are n (%), Mean (SD), or Median (Range), Unless Otherwise Indicated

	Baseline	2nd Year of Follow-Up			P
	Azithromycin (N=41)	Azithromycin (N=14)	No-Maintenance(N=27)
Men	22 (47%)	5 (36%)	15 (56%)
Age	64.7 (10.2)
COPD GOLD stages
GOLD I	0 (0%)	0 (0%)	0 (0%)		NS
GOLD II	15 (36.6%)	2 (21.4%)	12 (44.4%)		NS
GOLD III	13 (31.7%)	4 (28.6%)	9 (33.3%)		NS
GOLD IV	13 (31.7%)	7 (50%)	6 (22.2%)		NS
Smoking	20 (43%)	7 (50%)	9 (33%)
Pack years		40.3 (15.4)	39.2 (17.1)		NS
Total exacerbations median [IQR]	1.00 [IQR 0 −3.00]	1.50 [IQR 0–3.25]	1.00 [IQR 0–2.00]		NS
Hospital admission/severe exacerbation median [IQR]	0 [IQR 0–1.00]	0 [IQR 0–3.00]	0 [IQR 0–1.00]		NS
Time-to-exacerbation (days) median [IQR]		138 [IQR 57–189]	168 [IQR 91–222]		NS
FEV1 (L) Median [IQR]	1.03[IQR 0.72–1.26]^	0.81 [IQR 0.64 −1.07]	0.96 [IQR 0.77–1.26]		NS
FEV1 (% predicted) Median [IQR]	42 [IQR 28–58]^	30 [IQR 26–36]	43 [IQR 34–54]		0.039

Note: ^Measurement at month 12 of the Columbus trial.

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NS, not significant; IQR, interquartile range.